# Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

> **NCT06144606** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 60 (estimated)

## Conditions studied

- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Tecartus

## Key facts

- **NCT ID:** NCT06144606
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2028-11-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144606, "Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06144606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*